8-K: Candel Therapeutics Announces Promising Survival Data for CAN-3110 in Brain Cancer Trial

Candel Therapeutics reports encouraging survival data and immune response from its CAN-3110 trial in recurrent high-grade glioma, presented at the International Oncolytic Virotherapy Conference.

Summary

• Candel Therapeutics presented new data from its ongoing phase 1b clinical trial of CAN-3110 for recurrent high-grade glioma (rHGG) at the International Oncolytic Virotherapy Conference.
• The data from the multiple injection cohort showed improved survival compared to historical controls, with 3 out of 6 patients alive more than one year after treatment initiation (12.2, 13.0, and 18.7 months).
• Biopsies after CAN-3110 administration revealed a near absence of tumor cells and dense lymphocyte infiltrates, suggesting radiologic pseudo-progression.
• The company also presented a new multimodal immunotherapy candidate from its enLIGHTEN Discovery Platform, which showed significant tumor growth inhibition in preclinical models.
• Candel's lead experimental medicine, CAN-2409, was also highlighted, with over 1,000 patients dosed and a favorable tolerability profile.

Sentiment

Score: 8

Explanation: The document presents very positive clinical data and preclinical results, suggesting a strong potential for Candel's therapies. The survival data and immune response observed in the CAN-3110 trial are particularly encouraging. The company is also actively advancing multiple programs and has a favorable tolerability profile for its lead candidate. However, the forward-looking statements and risks associated with drug development temper the overall sentiment slightly.

Positives

• CAN-3110 shows promising survival data in rHGG patients, with some patients living over a year after treatment.
• The treatment appears to induce a strong immune response, with tumor cell reduction and lymphocyte infiltration.
• The enLIGHTEN Discovery Platform is producing promising new multimodal immunotherapy candidates.
• CAN-2409 has a favorable tolerability profile and has been tested in over 1,000 patients.
• The company is actively advancing multiple clinical and preclinical programs.

Risks

• The company's forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.
• The company's ability to continue as a going concern is a risk factor.
• Final data from clinical trials may differ from reported interim data.
• The company faces risks related to obtaining and maintaining regulatory approval for its product candidates.

Future Outlook

The company is focused on advancing its clinical and preclinical programs, including CAN-3110 and CAN-2409, and developing new therapies through the enLIGHTEN Discovery Platform. They are also looking to translate groundbreaking discoveries into potential clinical candidates.

Management Comments

• Francesca Barone, MD, PhD, stated that the data from the phase 1b trial shows CAN-3110's ability to trigger immune system activation and tumor clearance associated with improved survival.
• Paul Peter Tak, MD, PhD, FMedSci, noted that the data presented at IOVC underscores the transformative potential of Candel's therapeutic approach and that they are excited by the encouraging overall survival data after CAN-3110 experimental treatment.

Industry Context

This announcement is significant in the context of the broader oncology field, where there is a growing interest in immunotherapies and oncolytic viruses. Candel's approach of combining oncolysis with immune activation is aligned with current trends in cancer treatment. The company is also leveraging advanced discovery platforms to develop new therapies, which is a common strategy in the biotech industry.

Comparison to Industry Standards

• The survival data for CAN-3110 in rHGG is being compared to historical controls, which is a common practice in early-stage clinical trials.
• The use of oncolytic viruses and multimodal immunotherapies is a growing area of research, with companies like Amgen (Imlygic) and others exploring similar approaches.
• Candel's enLIGHTEN Discovery Platform is similar to other companies' efforts to develop novel therapeutic candidates through advanced research and analytics.
• The focus on delivering cytokines like IL-12 and IL-15 to the tumor microenvironment is a strategy being pursued by other companies, but Candel's approach using the Alpha-201 vector is unique.
• The favorable tolerability profile of CAN-2409 is a positive sign, as many cancer therapies are limited by adverse events. This is similar to other companies that are developing targeted therapies with the goal of reducing side effects.

Stakeholder Impact

• Shareholders may view the positive clinical data as a positive sign for the company's future.
• Patients with rHGG may benefit from the promising results of the CAN-3110 trial.
• Employees may be motivated by the progress of the company's research and development efforts.
• The company's success could lead to new partnerships and collaborations with other organizations.

Next Steps

• The company will continue to evaluate the effects of multiple CAN-3110 injections in rHGG.
• Candel will continue to advance its clinical trials for CAN-2409 in NSCLC, PDAC, and prostate cancer.
• The company will continue to develop new therapies through the enLIGHTEN Discovery Platform.

Key Dates

Keywords

Oncolytic Virotherapy, Immunotherapy, CAN-3110, CAN-2409, Recurrent High-Grade Glioma, rHGG, enLIGHTEN Discovery Platform, Tumor Microenvironment, Clinical Trial, Survival Data